Small-molecule inhibitor: melagatran
Name
- Common name
- melagatran
- Other names
- exanta; H376/95; ximelagatran (prodrug of melagatran)
Inhibition
- History
- Melagatran was described as a new thrombin inhibitor in 1998 (Gustafsson et al., 1998; Nilsson et al., 1998).
- Peptidases inhibited
- Inhibits thrombin (Ki = 2 nM: Gustafsson et al., 1998).
- Mechanism
- Inhibition is reversible, and was characterised in detail by Nilsson et al. (1998).
- Pharmaceutical relevance
- Melagatran is one of the anti-coagulant agents that act as "direct" thrombin inhibitors (others being hirudin and argatroban). Anticoagulants that act less directly include warfarin, which interferes with the biosynthesis of the gamma-carboxyglutamate-containing coagulation factors, and heparin, which potentiates inhibition of thrombin by antithrombin.
- DrugBank
- DB04898
Chemistry
- CID at PubChem
- 183797
- ChEBI
- 102451
- Structure
![[melagatran (S01.217 inhibitor) structure ]](/merops/smi/structures/melagatran.gif)
- Chemical/biochemical name
- 2-[[(1R)-2-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]azetidin-1-yl]-1-cyclohexyl-2-oxo-ethyl]amino]acetic acid
- Formula weight
- 429
General
- Comment
- After oral administration, ximelagatran is rapidly absorbed and converted to its active form, melagatran (Clement & Lopian, 2003).
